6 CONCLUSÕES
1) No período médio de quatro anos de seguimento, nenhuma das 57 crianças portadoras da mutação TP53 R337H, parentes de pacientes
com TCA e portadores da mesma mutação, desenvolveu TCA.
2) Estes dados não permitem, até o momento, confirmar que crianças portadoras da mutação TP53 R337H têm risco cumulativo de 9,9% de desenvolver TCA na infância.
REFERÊNCIAS
ACHATZ, M. I. W. et al. The TP53 mutation, R337H, is associated with Fraumeni and Li-Fraumeni-like syndromes in brazilian families. Cancer Lett, fev 20 [Epub ahead of print], 2006(a).
ACHATZ, M. I. W. et al. Response to "Germline TP53 R337H mutation is not sufficient to estabilish Li-Fraumeni or Li-Fraumeni-like syndrome", by Ribeiro et al. Cancer Lett, jun 7 [Epub ahead of print], 2006(b).
AMERICAN ACADEMY OF PEDIATRICS – COMMITTEE ON BIOETHICS. Ethical Issues with genetic testing in pediatrics. Pediatrics, v.107, n.6, p.1451-1455, 2001.
AMERICAN SOCIETY OF CLINICAL ONCOLOGY. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol, v.21, n.12, p.2397-2406, 2003.
BACHINSKI, L. L. et al. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res, v.65, n.2, p.427-431, 2005.
BELL, D. W. et al. Heterozigous germ line hCHK2 mutations in Li-Fraumeni syndrome.
Science, v.286, n.5449, p.2528-2531, 1999.
BERNSTEIN, L.; GURNEY, J. G. Carcinomas and other malignant neoplasms – Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. Disponível em: <htpp://seer.cancer.gov/publications/childhood/carcinomas.pdf>. Acesso em: 28 abr. 2006.
BIRCH, J. M.; BLAIR, V. Increase in childhood carcinomas in north-west England. Lancet, v.1, n.8589, p.833, 1988.
BIRCH, J. M. et al. Cancer in the families of children with soft tissue sarcoma. Cancer, v.15, p.2239-2248, 1990.
BIRCH, J. M. et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res, v.54, p.1298-1304, 1994.
BIRCH, J. M. et al. Relative frequency and morphology of cancers in carriers of germline
TP53 mutations. Oncogene, v.20, p.4621-4628, 2001.
BOTTOMLEY, R. H.; CONDIT, P. T.; CHANES, R. E. Cytogenetic studies in familial malignancy. Clin Res, v.15, p.334, 1967.
BOTTOMLEY, R. H.; CONDIT, P. T. Cancer families. Cancer Bull, v.20, p.22-24, 1968. BOTTOMLEY, R. H.; TRAINER, A. I.; CONDIT, P. T. Chromosome studies in a "cancer family". Cancer, v.28, p.519-528, 1971.
BRUGIÈRES. L. et al. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res, v.53, p.452-455, 1993.
CADWELL, C.; ZAMBETTI, G. P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene, v. 277, p.15-30, 2001.
CHERNAUSEK, S. D. Pheocromocytoma and the multiple endocrine neoplasia syndromes. In: SPERLING, M. A. Pediatric Endocrinology. Philadelphia: Saunders, 2002. p.439-454. CHOMPRET, A. et al. P53 germline mutations in childhood cancers and cancer risk for carriers individuals. Br J Cancer, v. 82, n.12, p.1932-1937, 2000.
CHOMPRET, A. et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet, v.38, p.43-47, 2001.
DAVISON, T. S. et al. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni like syndrome. Oncogene, v.17, p.651-656, 1998. DESANDES, E. et al. Cancer incidence among children in France, 1990-1999. Pediatr Blood Cancer, v.43, p.749-757, 2004.
DiGIAMMARINO, E. L. et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol, v.9, n.1, p.12-16, 2002.
D'AMATO, C.; TORRES, J. P. M.; MALM, O. DDT (diclorofenil tricloroetano): toxicidade e contaminação ambiental – uma revisão. Quim Nova, v.25, n.6, p.995-1002, 2002. EELES, R. A. et al. The role of TP53 in breast cancer development. Cancer Surv, v.18, p.57-75, 1993.
FIGUEIREDO, B. C. et al. Multiple childhood adrenocortical tumors in six families from Southern Brazil without Li-Fraumeni syndrome. Horm Res, v.53 (suppl. 2), p.15, 2000. FIGUEIREDO, B. C. et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab, v.90, n.2, p.615-619, 2005.
FIGUEIREDO, B. C. et al. Penetrance of adrenocortical tumors associated with the germline
TP53 R337H mutation. J Med Genet, v.43, p.91-96, 2006.
FISHER, D. A. The Quest Diagnostics Manual. Pediatric Endocrinology. San Juan Capistano, CA, Quest Diagnostic Incorporated, 2000, p.40.
FREBOURG, T. et al. Le syndrome de Li-Fraumeni: mise au point, données nouvelles et recommendations pour la prise en charge. Bull Cancer, v.88, n.6, p.581-587, 2001. GALLO, C. V. M. et al. TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives. Mutat Res, v.589, n.3, p.192-207, 2005. HAINAUT, P. Tumor-specific mutations in p53: the acid test. Nat Med, v.8, p.21-23, 2002. HELMAN, L. J.; MALKIN, D. Molecular biology for childhood cancers. In: DEVITA JR., V. T.; HELLMAN, S.; ROSENBERG, S. A. (Ed.). Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincot Williams & Wilkins, 2005. p.1889-1897.
HEPPNER, C. et al. MEN 1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab, v.84, n.1, p.216-219, 1999.
HISADA, M. et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst, v.90, n.8, p.606-611, 1998.
KINZLER, K. W.; VOGELSTEIN, B. Colorectal tumors. In: SCRIVER, C. R.; BEAUDET, A. L.; SLY, W. S. e VALLE, D. (Ed.). The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995. p.643-663.
LACK, E. E. et al. Adrenocortical neoplasm in the pediatric and adolescent age group: clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors.
Pathol Ann, v.27, p.1-53, 1992.
LAIRMORE, T. C.; MOLEY, J. F. Molecular biology of endocrine tumors. In: DEVITA JR., V. T.; HELLMAN, S.; ROSENBERG, S. A. (Ed.). Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincot Williams & Wilkins, 2005. p.1489-1503
LATRONICO, A. C. et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab, v.86, p.4970-4973, 2001.
LEFEVRE, M. et al. Adrenal cortical carcinoma in 42 patients treated from 1958 to 1980 at Villejuif. In: HUMPHREY, G. B.; GRINDEY, G. B.; DEHNER, L. B. et al. (Ed.). Adrenal and endocrine tumors in children. Boston: Martinus Nijhoff Publishers, 1984. p.256-276. LEVINE, A. J. p53, the cellular gatekeeper for growth and division. Cell, v.88, p.323-331, 1997. LI, F. P.; FRAUMENI JR., J. F. Soft – tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann Int Med, v.71, n.4, p.747-752, 1969.
LI, F. P.; FRAUMENI JR., J. F. Familial breast cancer, soft tissue sarcomas, and other neoplasms.
Ann Int Med, v.83, n.6, p.833-834, 1975.
LI, F. P.; FRAUMENI JR., J. F. Prospective study of a cancer familial syndrome. JAMA, v.247, p.2292-2294, 1982.
LI, F. P. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res, v.48, p.5358-5362, 1988.
LIBÉ, R.; BERTHERAT, J. Molecular genetics of adrenocortical tumors, from familial to sporadic diseases. Eur J Endocrinol, v.153, p.477-487, 2005.
LINZER, D. I.; LEVINE, A. J. Characterization of a 54-Kdalton cellular SV40 transformed cells and uninfected embryonal carcinoma cells. Cell, v.17, p.43-52, 1979.
LJUNGMAN, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.
Neoplasia, v.2, n.3, p.208-225, 2000.
LOMAX, M. E. et al. Two functional assays employed to detect an unusual mutation in the oligomerization domain of p53 in a Li-Fraumeni like family. Oncogene, v.14, n.15, p.1869-1874, 1997.
LOMAX, M. E. et al. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene, v.17, p.643-649, 1998. LONGUI, C. A. et al. Inhibin α-subunit (INHA) gene and locus changes in paediatric
adrenocortical tumors from TP53 R337H mutation heterozygote carriers. J Med Genet, v.41, p.354-359, 2004.
LYNCH, H. T. et al. Genetic and pathologic findings in a kindred with hereditary sarcoma breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma.
Cancer, v.41, p.2055-2064, 1978.
MALKIN, D. et al. Gem line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, v.250, p.1233-1238, nov. 1990.
MALKIN, D. et al. Germline mutations of the p53 tumor-supressor gene in children and young adults with second malignant neoplasms. N Engl J Med, v.326, n.20, p.1309-1314, 1992. MARIGO, C.; MULLER, H.; DAVIES, J. N. P. Survey of cancer in children admitted to a Brazilian charity hospital. J Natl Cancer Inst, v.43, n.6, p.1231-1240, dez. 1969. MARSH, D. J.; ZORI, R. T. Genetic insights into familial cancers – update and recent discoveries. Cancer Lett, v.181, p.125-164, 2002.
MARSHALL, W. A.; TANNER, J. M. Variations in the pattern of pubertal changes in boys.
Arch Dis Child, v.45, p.13-23, 1970.
MARQUES-PEREIRA, R. et al. Tumores do Córtex Adrenal na Infância. Arq Bras Endocrinol Metab, v.48, p.651-658, 2004.
MARQUES-PEREIRA, R. et al. Tratamento do tumor do córtex adrenal na infância. Arq Bras Endocrinol Metab, v.49, n.5, p.747-752, 2005.
MARQUES-PEREIRA, R. et al. Childhood adrenocortical tumors: a review. Hered Cancer Clin Practice, v.4, n.2, p.81-89, 2006.
MATEU, M. G.; FERSHT, A. R. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumor suppressor p53 tetramerization domain. EMBO J, v.17, n.10, p.2748-2758, 1998.
MATLOFF, E. T. Genetic counseling. In: DEVITA JR., V. T.; HELLMAN, S. e ROSENBERG, S. A. (Ed.). Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincot Williams & Wilkins, 2005. p.2676-2683.
MICHALKIEWICZ, E. et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol, v.5, p.838-845, 2004
MILLER, W. L. The adrenal cortex. In: SPERLING, M. A. (Ed.). Pediatric Endocrinology. Philadelphia: Saunders, 2002. p.385-438.
MÜLLER, H. et al. Genetic testing for cancer predisposition – an ongoing debate. Lancet Oncol, v.1, p.118-124, 2000.
NELSON, R. M. et al. Ethical issues with genetic testing in pediatrics. Pediatrics, v.107, n.6, p.1451-1455, 2001.
OLIVIER, M. et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res, v.63, p.6643-6650, 2003.
PARKIN, D. M. et al. The international incidence of childhood cancer. Int J Cancer, v.42, p.511-520, 1988.
PIANOVSKI, M. A. D. et al. Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr Blood Cancer, v.47, n.1, p.56-60, 2006(a).
PIANOVSKI, M. A. D. et al. SF-1 overexpression in childhood adrenocortical tumors. Eur J Cancer, v. 42, n.8, p.1040-1043, 2006(b).
PINTO, E. M. et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metab, v.48, n.5, 2004.
PINTO, E. M. et al. Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the arg227His mutation of the p53 tumor suppressor protein. J Clin Endocrinol Metab, v.90, n.5, p.2976-2981, 2005.
RIBEIRO, R. C. et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Nat Acad Sci USA, v.98, p.9330-9335, 2001. RIBEIRO, R. C. et al. Germline TP53 R337H mutation is not sufficient to estabilish Li-Fraumeni or Li-Li-Fraumeni-like syndrome. Cancer Lett, jun 1 [Epub ahead of print], 2006. SAMESHIMA, Y. et al. Detection of novel germ-line p53 mutations in diverse cancer-prone families identified by selecting patients with adrenocortical carcinoma. J Natl Cancer Inst, v.84, n.9, p.703-711, mai. 1992.
SANDRINI, F. Tumor adrenocortical em crianças: avaliação da relação com câncer em familiares e com alterações no gene TP53. Curitiba, 1999. 58f. Dissertação (Mestrado em Pediatria) – Setor de Ciências da Saúde, Universidade Federal do Paraná.
SANDRINI, F. et al. Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. Horm Metab Res, v.37, p.231-235, 2005.
SANDRINI, R.; RIBEIRO, R. C.; DeLACERDA, L. Childhood adrenocortical tumors. J Clin Endocrinol Metab, v.82, p.2027-31, 1997.
SCHULTE, K. M. et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN 1 gene in adrenal cancer. J Clin Endocrinol Metab, v.85, n.1, p.441-448, 2000.
SIFRI, R.; GANGADHARAPPA, S.; ACHESON, L. S. Identifyng and testing for hereditary suceptibility to common cancers. CA Cancer J Clin, v.54, p.309-326, 2004.
STRATAKIS, C. A. Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab, v.14, n.9, p.404-410, 2003.
TANNER, J.; WITHEHOUSE, R. Clinical longitudinal standards for height, weight, height velocity and weight velocity and stages og puberty. Arch Dis Child, v.51, p.170-179, 1976. VARLEY, J. M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mut, v.21, p.313-320, 2003.
VARLEY, J. M. et al. A previously undescribed mutation within the tetramerization domain of
TP53 in a family with Li-Fraumeni syndrome. Oncogene, v.12, p.2437-2442, 1996. VARLEY, J. M. et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res, v.57, p.3245-3252, 1997.
VARLEY, J. M. et al. Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet, v.65, n.4, p.995-1006, 1999.
VOGELSTEIN, B.; LANE, D.; LEVINE, A. J. Surfing the p53 network. Nature, v.408, p.307-310, 2000.
WAGNER, J. et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst, v. 86, n. 22, p. 1707-1710, 1994.
WAJCHENBERG, B. L. et al. Adrenocortical carcinoma. Clinical and laboratory observations.
Câncer, v.88, p.711-736, 2000.
WOOTEN, M. D.; KING, D. K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer, v.72, n.11, 1993.